morphinans and Schizophrenia

morphinans has been researched along with Schizophrenia* in 5 studies

Reviews

1 review(s) available for morphinans and Schizophrenia

ArticleYear
[Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2010, Volume: 30, Issue:5-6

    Nalfurafine hydrochloride, a kappa-opioid receptor agonist, was approved in January 2009 and released to the market on March 2009 for the indication of "Improvement of pruritus in hemodialysis patients (only for cases resistant to conventional treatments)" in Japan (Brand Name: REMITCH CAPSULES 2.5 microg, Marketing Authorization Holder: Toray Industries, Inc., Distributed by Torii Pharmaceutical Co., Ltd., Co-developed by Japan Tobacco Inc.). In addition to antipruritic effect, nalfurafine hydrochloride showed ameliorating effects on pain, neuropathic pain, drug dependence, schizophrenia and dyskinesia in non-clinical studies. Therefore, nalfurafine hydrochloride may become a useful therapeutic agent for their diseases.

    Topics: Analgesics; Animals; Antipruritics; Disease Models, Animal; Drug Tolerance; Dyskinesias; Humans; Mice; Morphinans; Rats; Receptors, Opioid, kappa; Schizophrenia; Spiro Compounds; Substance Withdrawal Syndrome

2010

Trials

1 trial(s) available for morphinans and Schizophrenia

ArticleYear
Some methodological considerations in the evaluation of drug-induced extrapyramidal disorders: a study of Ex10-029, a new morphanthridine derivative.
    The Journal of clinical pharmacology and new drugs, 1972, Volume: 12, Issue:4

    Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Biperiden; Chronic Disease; Clinical Trials as Topic; Cyclohexylamines; Evaluation Studies as Topic; Handwriting; Humans; Male; Middle Aged; Morphinans; Movement Disorders; Parkinson Disease; Psychiatric Status Rating Scales; Schizophrenia; Sulfonic Acids; Time Factors; Tranquilizing Agents

1972

Other Studies

3 other study(ies) available for morphinans and Schizophrenia

ArticleYear
Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
    European journal of pharmacology, 2009, Mar-15, Volume: 606, Issue:1-3

    Abnormalities in dopaminergic and serotonergic neurotransmission in the forebrain are believed to be involved in the underlying mechanism of schizophrenia; therefore, the direct blockade of the receptors associated with these systems is a central strategy for schizophrenia treatment, even though this strategy concurrently produces adverse effects like extrapyramidal effects. Kappa opioid receptors exist extensively in the brain and recent reports have suggested that these receptors are involved in modulating the release of several neurotransmitters including dopamine and serotonin. In the present study, we investigated the effect of TRK-820, (E)-N-[17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6beta-yl]-3-(furan-3-yl)-N-methylprop-2-enamide monohydrochloride, a selective kappa opioid receptor agonist, on phencyclidine-induced rat behavioral changes and on biochemical changes in the prefrontal cortex. First, TRK-820 dose-dependently inhibited phencyclidine-induced rat hyperlocomotion, which is one of the abnormal behaviors recognized as a rodent schizophrenia model. The inhibitory effect was completely antagonized with nor-BNI (nor-binaltorphimine hydrochloride), a selective kappa opioid receptor antagonist. Second, TRK-820 dose-dependently inhibited phencyclidine-induced stereotyped behaviors including head-weaving, which is considered a behavioral syndrome based on the impairment of the serotonergic system. Third, in an in vivo microdialysis study, TRK-820 dose-dependently attenuated the biochemical changes of both dopamine and serotonin in the prefrontal cortex of rats treated with phencyclidine without affecting their basal levels in normal rats. The initial findings that TRK-820 potentially modulates such monoamine changes and ameliorates abnormal behaviors related to their changes may suggest its therapeutic potential against the symptoms of schizophrenia.

    Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Extracellular Space; Hyperkinesis; Male; Morphinans; Naltrexone; Phencyclidine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Schizophrenia; Serotonin; Spiro Compounds

2009
Effect of GNTI, a kappa opioid receptor antagonist, on MK-801-induced hyperlocomotion and stereotypy in mice.
    Acta pharmacologica Sinica, 2006, Volume: 27, Issue:11

    To examine the effect of GNTI [5'-guanidinyl-17-(cyclopropylmethyl)-6,7- dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphinan], a selective antagonist for the kappa opioid receptor, in the MK-801 (dizocilpine maleate)-induced behavioral model of psychosis in schizophrenia as a way to explore the involvement of the kappa opioid receptor in modulating psychotic symptoms of schizophrenia.. Two doses of MK-801 (0.3 mg/kg and 0.6 mg/kg) were administered by systemic injection in mice to induce psychosis-like behavior as a rodent schizophrenia model, preceded by an injection of different doses of GNTI. Both locomotion and stereotypy were measured as the behavioral endpoints for quantitative analysis.. GNTI inhibited MK-801-induced hyperlocomotion and stereotypy. In particular, GNTI showed differential modulation of stereotypy induced by 0.3 mg/kg vs 0.6 mg/kg MK-801.. Antagonism of kappa opioid receptors attenuates MK-801-induced behavior, suggesting a potential involvement of the kappa opioid receptor in psychosis-like symptoms of schizophrenia. GNTI appears to be a useful pharmacological tool to explore the kappa opioid receptor function in vivo.

    Topics: Animals; Dizocilpine Maleate; Guanidines; Locomotion; Male; Mice; Mice, Inbred BALB C; Morphinans; Receptors, Opioid, kappa; Schizophrenia; Stereotyped Behavior

2006
Tritiated etorphine and naloxone binding to opioid receptors in caudate nucleus in schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1985, Volume: 146

    Opioid receptor binding sites were assessed in membrane preparations of caudate nucleus from post-mortem brains of controls and of patients with schizophrenia. There was no difference between the two groups in the total specific binding of 3H-etorphine or in its 'mu' and ('delta + kappa') components. Similarly, the binding of 3H-naloxone did not differ between patients and controls. It is concluded that a previous report of reduced opioid receptors in caudate of schizophrenics is unlikely to prove a consistent finding and that the results of the present study offer no support to the claim that there is a general disturbance in opiate mechanisms in schizophrenia.

    Topics: Aged; Caudate Nucleus; Etorphine; Female; Humans; Male; Middle Aged; Morphinans; Naloxone; Receptors, Opioid; Schizophrenia; Tritium

1985